These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

957 related articles for article (PubMed ID: 32844196)

  • 1. Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
    Cilia R; Cereda E; Akpalu A; Sarfo FS; Cham M; Laryea R; Obese V; Oppon K; Del Sorbo F; Bonvegna S; Zecchinelli AL; Pezzoli G
    Brain; 2020 Aug; 143(8):2490-2501. PubMed ID: 32844196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.
    Cilia R; Akpalu A; Sarfo FS; Cham M; Amboni M; Cereda E; Fabbri M; Adjei P; Akassi J; Bonetti A; Pezzoli G
    Brain; 2014 Oct; 137(Pt 10):2731-42. PubMed ID: 25034897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effectiveness of trihexyphenidyl and levodopa on motor symptoms in Parkinson's disease.
    Sahoo LK; Holla VV; Batra D; Prasad S; Bhattacharya A; Kamble N; Yadav R; Pal PK
    J Neural Transm (Vienna); 2020 Dec; 127(12):1599-1606. PubMed ID: 33037478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to levodopa in Parkinson's disease over time. A 4-year follow-up study.
    Santos-García D; de Deus Fonticoba T; Cores Bartolomé C; Feal Painceiras MJ; García Díaz I; Íñiguez Alvarado MC; Paz JM; Jesús S; Cosgaya M; García Caldentey J; Caballol N; Legarda I; González Aramburu I; Ávila Rivera MA; Gómez Mayordomo V; Vela L; Escalante S; Mendoza Z; Martínez Castrillo JC; Alonso PS; Alonso Losada MG; López Ariztegui N; McAfee D; Martinez-Martin P; Mir P;
    Parkinsonism Relat Disord; 2023 Nov; 116():105852. PubMed ID: 37804623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Follow-Up of the LEAP Study: Early Versus Delayed Levodopa in Early Parkinson's Disease.
    Frequin HL; Verschuur CVM; Suwijn SR; Boel JA; Post B; Bloem BR; van Hilten JJ; van Laar T; Tissingh G; Munts AG; Dijk JM; Lang AE; Dijkgraaf MGW; Hoogland J; de Bie RMA;
    Mov Disord; 2024 Jun; 39(6):975-982. PubMed ID: 38644623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
    Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
    Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
    J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial of Lixisenatide in Early Parkinson's Disease.
    Meissner WG; Remy P; Giordana C; Maltête D; Derkinderen P; Houéto JL; Anheim M; Benatru I; Boraud T; Brefel-Courbon C; Carrière N; Catala H; Colin O; Corvol JC; Damier P; Dellapina E; Devos D; Drapier S; Fabbri M; Ferrier V; Foubert-Samier A; Frismand-Kryloff S; Georget A; Germain C; Grimaldi S; Hardy C; Hopes L; Krystkowiak P; Laurens B; Lefaucheur R; Mariani LL; Marques A; Marse C; Ory-Magne F; Rigalleau V; Salhi H; Saubion A; Stott SRW; Thalamas C; Thiriez C; Tir M; Wyse RK; Benard A; Rascol O;
    N Engl J Med; 2024 Apr; 390(13):1176-1185. PubMed ID: 38598572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
    Hoy SM; Keating GM
    Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.